ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 406 - 420 of 5996 products
BioCity Approved to Start US Trial of Bispecific Antibody for Solid Tumors
$5.00
Available
Investisbio Out-Licenses KRAS G12C Inhibitor to Sino Biopharm Subsidiary
$5.00
Available
BeiGene’s Breakup with Celgene/BMS Now Complete with Return of BeiGene Shares
$5.00
Available
Gracell Raises $100 Million in Private Placement for Trials of CAR-T Candidates
$5.00
Available
Duality Biologics Adds Third ADC Candidate to BioNTech Partnership
$5.00
Available
Mundipharma May Propose Sale of China Operations for $1 Billion
$5.00
Available
LianBio Starts China Trials of SHP2 Inhibitor for NSCLC with EGFR Mutations
$5.00
Available
Oramed and Hefei Tianhui to Form $60 Million JV for Oral Insulin Product
$5.00
Available
Doer Biologics Starts Trial of Tri-Specific Drug for Obesity
$5.00
Available
ABVC Out-licenses China Rights for Two Neurologic Therapies to Xinnovation
$5.00
Available
CASI Acquires China Rights to Lymphoma Chemotherapy from Mundipharma
$5.00
Available
CirCode Forms Partnership with Pfizer to Develop Circular RNA Therapeutics
$5.00
Available
Xinkanghe Biomedical Raises $14 Million for Immunology Drugs
$5.00
Available
Leads Biolabs Approved to Start China/US Trials of Bispecific for Multiple Myeloma
$5.00
Available
Transcenta to Start Phase II Trial of Osteoporosis Therapy in China
$5.00
Available